83
Participants
Start Date
March 15, 2017
Primary Completion Date
August 15, 2021
Study Completion Date
March 10, 2023
Blinatumomab
"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
University Hospital of Frankfurt (Main), Frankfurt am Main
Charité - Campus Benjamin Franklin, Berlin
Uniklinik Dresden, Dresden
Uniklinik Düsseldorf, Düsseldorf
Univeristätsklinikum Essen, Essen
Universitätsklinikum Freiburg, Freiburg im Breisgau
Universitätsmedizin Göttingen, Göttingen
Uniklinik Hamburg Eppendorf, Hamburg
Medizinische Hochschule Hannover, Hanover
Uniklinik Heidelberg, Heidelberg
UKSH-Kiel, Kiel
Universitätsklinik Leipzig, Leipzig
Klinikum Mannheim, Mannheim
Universitätsklinkum Gießen und Marburg, Marburg
Klinikum Großhadern, München
Uniklinik Münster, Münster
Klinikum Nürnberg Nord, Nuremberg
Uniklinik Regensburg, Regensburg
Robert - Bosch - Krankenhaus, Stuttgart
Universitätsklinik Tübingen, Tübingen
Universitätsklinkum Ulm, Ulm
Uniklinik Würzburg, Würzburg
Lead Sponsor
Goethe University
OTHER